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Abstract
Background: Duchenne and Becker Muscular dystrophies (DMD/BMD) are allelic disorders caused by mutations in
the dystrophin gene, which encodes a sarcolemmal protein responsible for muscle integrity. Deletions and
duplications account for approximately 75% of mutations in DMD and 85% in BMD. The implementation of
techniques allowing complete gene sequencing has focused attention on small point mutations and other
mechanisms underlying complex rearrangements.
Methods: We selected 47 patients (41 families; 35 DMD, 6 BMD) without deletions and duplications in DMD gene
(excluded by multiplex ligation-dependent probe amplification and multiplex polymerase chain reaction analysis).
This cohort was investigated by systematic direct sequence analysis to study sequence variation. We focused our
attention on rare mutational events which were further studied through transcript analysis.
Results: We identified 40 different nucleotide alterations in DMD gene and their clinical correlates; altogether, 16
mutations were novel. DMD probands carried 9 microinsertions/microdeletions, 19 nonsense mutations, and 7
splice-site mutations. BMD patients carried 2 nonsense mutations, 2 splice-site mutations, 1 missense substitution,
and 1 single base insertion. The most frequent stop codon was TGA (n = 10 patients), followed by TAG (n = 7) and
TAA (n = 4). We also analyzed the molecular mechanisms of five rare mutational events. They are two frame-
shifting mutations in the DMD gene 3’end in BMD and three novel splicing defects: IVS42: c.6118-3C>A, which
causes a leaky splice-site; c.9560A>G, which determines a cryptic splice-site activation and c.9564-426 T>G, which
creates pseudoexon retention within IVS65.
Conclusion: The analysis of our patients’ sample, carrying point mutations or complex rearrangements in DMD
gene, contributes to the knowledge on phenotypic correlations in dystrophinopatic patients and can provide a
better understanding of pre-mRNA maturation defects and dystrophin functional domains. These data can have a
prognostic relevance and can be useful in directing new therapeutic approaches, which rely on a precise definition
of the genetic defects as well as their molecular consequences.
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Dystrophinopathies are a heterogeneous group of disor-
ders caused by mutations in dystrophin (DMD) gene [1].
Duchenne Muscular Dystrophy (DMD; OMIM #310200)
is the most severe form, with an incidence of 1 in 3,500
newborn males [2] and loss of independent ambulation
before the age of 14 years [3]. Becker Muscular Dystro-
phy (BMD; OMIM #300376) is a milder and more het-
erogeneous allelic disorder with near-normal life
expectancy [4].
Until recently, the genetic approach was limited to
methods that were able to detect large deletions and
duplications because the large size of the DMD gene
made finer-scale mutation analysis prohibitively time
consuming. In DMD patients, they account for 65% and
10% of mutations, respectively; in BMD, the mutation
detection rate is 85% [5].
The recent implementation of diagnostic techniques
with possibility to perform high-throughput direct
sequencing of the DMD gene [6] has increased diagnos-
tic sensitivity and focused attention on small point
mutations and more complex gene rearrangements that
otherwise would hardly be detected.
The analysis of both types of mutations, the study of
their positions along the DMD gene and their effects on
the transcript processing and protein levels helps to
define the correlations with clinical presentation and to
build a clear understanding of the molecular pathology of
dystrophinopathies. The described single nucleotide
substitutions and small nucleotide changes along the
coding sequence, together with other more complex
DMD gene rearrangements, are listed on the Leiden web-
site http://www.dmd.nl/ and described in several works
[7-12]. Knowledge about these small nucleotide changes
can provide a better understanding of dystrophin func-
tional domains, as well as the mechanisms underlying
transcriptional and post-transcriptional events.
The overall number of described pre-RNA maturation
defects and deep intronic mutations in the DMD gene is
still relatively small, and their effects on mRNA proces-
sing and protein expression are often unknown
[10,13-17]. The clinical usefulness of drawing conclu-
sions about the prognosis of a given mutation based on
a single or few reports is questionable.
Furthermore, the development of several new thera-
peutic approaches for DMD strongly relies on a precise
definition of the genetic defects as well as their molecu-
lar consequences. Indeed, fundamental areas of thera-
peutic research on DMD/BMD are currently based on
the usage of molecules that promote the read-through
of pathological stop codons created by point mutations
[18,19]. A similar need for deeper understanding applies
to the entire field of exon-skipping technologies based
on our current knowledge of the process, which
naturally regulates dystrophin mRNA maturation [20].
From this point of view, the analysis of naturally occur-
ring aberrant splicing events might be instructive
regarding the complex transcriptional mechanisms of
the gigantic DMD gene.
Methods
Patient selection
A sample of 41 DMD and 6 BMD patients was shown
to be negative for both deletions and duplications in the
entire coding region of the DMD g e n e ,a sw e l la st h e
adjacent splice site and muscle promoter regions, by
multiplex ligation-dependent probe amplification
(MLPA) and multiplex polymerase chain reaction (PCR)
analysis.
Written informed consent was obtained (and pre-
served in original) from all subjects or their caregivers
at the time of primary diagnostic procedures, with expli-
cit consent to future uses for research purpose, accord-
ing to the Declaration of Helsinki. This protocol was
approved by the Institutional Review Board of the
Fondazione I.R.C.C.S. Ca’ Granda Ospedale Maggiore
Policlinico - University of Milan.
The “Telethon Bank of DNA, Nerve and Muscle
Tissues” (no. GTF02008), located in the Department of
Neurological Sciences, Fondazione I.R.C.C.S. Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy, was the
source of the DNA samples used in this study.
Thirty-five probands showed a DMD clinical pheno-
type and the absence of dystrophin protein in muscle
immunohistochemistry (IHC) and Western blot (WB)
analysis with multiple anti-dystrophin antibodies, while
six had a milder muscle involvement and variable mus-
cle dystrophin expression consistent with a diagnosis of
BMD.
In this cohort, we undertook a systematic study of
sequence variation, by direct sequence analysis. The
patients were regularly followed, with a complete clinical
evaluation comprising cardiac, respiratory, and cognitive
assessments.
Muscle tissue analysis
Muscle biopsy was taken from brachial biceps or quadri-
ceps muscle after written informed consent as pre-
viously reported. According to standard techniques, the
muscle sections were analyzed by morphological study
and IHC analysis. Dystrophin IHC was performed [21]
using monoclonal antibodies against mid-rod domain,
NH2, and COOH epitopes (Novocastra, Newcastle upon
Tyne, UK), and was completed using a-SG, b-SG, g-SG,
δ-SG, dysferlin (Novocastra), and caveolin-3 (Transduc-
tion Laboratories, Lexington, KY) monoclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) as
described [22-24]. Dystrophin defects revealed by IHC
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clonal antibodies.
Molecular analysis
DNA was extracted from peripheral blood samples
according to standard procedures (Flexi Gene DNA
Handbook, Quiagen). All patients were screened for
deletions and duplications with multiplex PCR and
MLPA as previously described [25].
Sequence analysis
All 79 exons and the exon-intron boundaries of the
DMD gene were studied through PCR amplification
and direct sequencing (ABI Prism 3100 Genetic
Analyzer, Applied Biosystem, Foster City, USA) using
published primer sets [26]. Mutations were named
according to the Leiden Muscular Dystrophy database
http://www.dmd.nl/ using the nomenclature system
published in 2000 on Human Mutation [27] (reference
sequence GenBank file NM_004006.1)
Transcript analysis
Patients with mutations leading to abnormal mRNA
splicing were further investigated through transcript
analysis. In these patients, mRNA was isolated from
muscle tissue with Eurozol (EMR055100, EuroClone).
The cDNA was produced through reverse transcription
polymerase chain reaction (RT-PCR) (Ready-To-Go
RT-PCR kit, Amersham Pharmacia) and analyzed by
amplification and sequencing. Transcript analysis was
performed using primers previously published by
Roberts et al. [26]. New primers were designed in
some specific cases. All primer sequences are available
on request.
Bioinformatics analysis
To estimate the effect of the T/G mutation in intron 65
of the DMD gene, we used the splice site models intro-
duced by Yeo and Burge [28] and the software available
at: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_-
scoreseq_acc.html. The sequences CTGGTAATT and
CTGGTAAGT, which correspond respectively to the
wild-type and mutated 5’ splice site of the included
exon were scored. We obtained maxENT scores, which
represents the probability that a sequence is a functional
splice site. Therefore, as suggested by Enl et al. [29],
given two sequences of differing scores, the higher-scor-
ing sequence has a higher likelihood of being used as 5’
splice site.
Results
We selected 47 patients (41 probands) carrying nucleo-
tide alterations in the DMD gene; 41 patients were
affected with DMD and 6 with BMD.
The distribution of the mutations in DMD families
was as follows: 9 micro-insertions or microdeletions, 19
nonsense substitutions, 7 splice-site mutations.
Among BMD subjects, 2 carried nonsense mutations,
2 showed splice-site mutations, 1 had a missense substi-
tution, and 1 patient presented with the insertion of a
single nucleotide (Figure 1). The most frequent stop
c o d o nw a sT G A( n=1 0p a t i e n t s )f o l l o w e db yT A G
8 64 70 79
p.Leu3485ProfsX6
p.Gln3595X
p.Trp118Arg
c.1705-8T>C p.Trp3X c.6118-3C>A
p.Leu51ProfsX37
p.Gln2118ArgfsX3
p.Lys2329SerfsX8
p.Glu2315X
p.Val535LeufsX47
p.Gln190X
p.Gln1194X
p.Gln1373X
p.Arg1737X
p.Arg1666X
p.Arg1844X
p.Gln1855X
p.Lys2093X p.Met2517GlyfsX49
p.Arg2680X
p.Arg2870X
p.Asn3068LysfsX19
p.Arg3034X
p.Arg2982X
p.Arg3370X
p.Arg3381X
p.Glu3407X
c.10086+1G>A
p.Asn3462LysfsX3
p.Gln3551X
p.Asp3187Gly
c.358-2A>T
c.2949+1G>T
p.Lys1004X
p.Gln986X
c.6118-1G>A
c.8668+3 A>T
p.Thr3188=fsX7
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Figure 1 Distribution of mutations along the DMD gene. Each box corresponds to an exon, with different colours indicating the four
different functional portions of the gene: actin-binding domain (exons 1-8, yellow); rod domain (exons 9-62, blue); cysteine-rich domain (exons
63-69, green); C-terminal domain (exons 70-79, red). Mutations identified in the BMD population are listed in the upper part of the figure, while
mutations found in the DMD population are listed in the lower section. Intronic mutations are listed in blue.
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16 mutations were novel.
The mean age at diagnosis of the entire DMD group
was 2.8 ± 1.3 years (range 1-6 years) while BMD
patients came to medical attention at approximately 14
± 20 years (range 3-46 years). Fifty-six percent of DMD
patients were wheelchair bound; they lost independent
ambulation at a mean age of 10.1 years. The clinical and
molecular characteristics of this population are summar-
ized in Table 1.
In the majority of patients, phenotype (DMD versus
BMD) was predicted by genotype, according to the read-
ing frame rule. However, we observed exceptions to this
rule in 2 of 34 DMD cases and 4 of 6 BMD cases.
Patient II, carrying the nonsense mutation p.Trp3X has
been previously described (patient VII, R007) [30]. Clini-
cal and molecular data regarding the other five cases,
relevant to the issue of the reading frame rule or pre-
senting rare aberrant mRNA maturation, are described
in detail.
Patient I: Creation of a stop codon at the 3’ end of the
DMD gene is associated with a mild BMD phenotype
A 7-year-old boy came to medical attention because of
occasionally high creatine kinase (CK) levels (12,922 IU/
L) during bladder infection. He was completely asymp-
tomatic, showing only mild calf hypertrophy and
Achilles tendon retraction, with no muscular weakness.
He had neither cardiac nor respiratory impairment. Full
Intelligence Quotient (IQ) level was normal.
A muscle biopsy performed on the brachial biceps at 7
years of age showed a mild dystrophic pattern with
moderate connective tissue incr e a s e ,f i b r es i z ev a r i a b i l -
ity, and 3-4 necrotic fibres. IHC revealed decreased reac-
tivity with antibody against NH2 and Rod-domain and
complete absence of signal with antibodies directed
towards the COOH-terminal epitope. Molecular analysis
demonstrated the presence of a single nucleotide inser-
tion in exon 74 (c.10453insC). This insertion leads to a
frame shift mutation with the creation of a premature
stop codon (p.Leu3485ProfsX6) (Figure 2A) and does
not fit with the mild clinical presentation of the patient.
The protein data were further confirmed by dystro-
phin WB analysis on muscle homogenate, which showed
the presence of a truncated protein lacking of the
C-terminal domain (Figure 2B); although decreased in
molecular weight and amount, this protein is still able
to localize to the membrane as demonstrated by IHC.
Patient III: Nonsense mutation located at the 3’ end of
the DMD gene is associated with a severe BMD
phenotype
This patient presented with a severe BMD phenotype.
He started to complain muscular impairment with
difficulties in running and climbing stairs at 9 years of
age. Motor involvement displayed a fast, progressive
course with loss of independent ambulation at 22
years of age. At 19 years of age, he also developed
severe cardiac involvement with arrhythmia and hypo-
cinesia. After 3 years, he presented with a reduction of
ejection fraction (40%) and started cardiac therapy. He
also presented with a restrictive respiratory pattern,
but did not require non-invasive mechanical ventila-
tion. At 27 years of age, this patient had stable clinical
parameters.
Muscle tissue analysis revealed a severe dystrophic
pattern and weak sarcolemmal signal with DYS rod-
domain antibodies. After exclusion of deletions and
duplications of the DMD gene, sequence analysis
showed a single nucleotide substitution (c.10783C>T)
(Figure 3) that is predicted to create a stop codon in
exon 75 (p.Gln3595X). This “null” mutation was also
compatible with partial dystrophin production, even if
the quantity of protein, as evaluated by WB analysis,
was lower than in the case of Patient I.
Patient VI: Leaky splice site mutation and double
transcript in a BMD patient
The patient showed a BMD phenotype with late onset,
at 49 years of age. He complained of pain, muscle wast-
ing of the quadriceps, and lower limb girdle muscle
weakness. Although the disease had a progressive
course, the patient was still ambulant at 68 years of age,
manifesting only mild difficulty in postural adjustments.
A muscle biopsy conducted at 50 years of age revealed
mild myopathic changes with a slight lipid increase.
A repeated biopsy performed at 58 years of age demon-
strated a dystrophic pattern with fibre size variability, as
well as several nuclear centralizations and fiber split-
tings. Connective tissue was normal in all samples. IHC
analysis revealed mild sarcolemmal staining with the
three antibodies. WB showed a mild intensity reduction
with both DYS1 and DYS2 antibodies, and sarcoglycan
immunostaining was also decreased. The screening of
the DMD gene for deletions and duplications with mul-
tiple-PCR and MLPA and the analysis of the four sarco-
glycan genes by direct sequencing showed no mutations.
DMD gene sequencing revealed a c.6118-3C>A
nucleotide substitution in IVS42 (Figure 4A). This novel
mutation is expected to determine the skipping of exon
42 with production of an out-of-frame transcript asso-
ciated with severe DMD phenotype.
The mild clinical presentation of Patient VI was
explained by transcript analysis.
In fact, study of the transcript revealed the presence of
two different products (Figure 4B): a 665-bp band corre-
sponding to full-length PCR products (Figure 4B, upper
transcript) and a more intense band of lower molecular
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Page 4 of 12Table 1 Clinical and molecular characteristics of patients carrying point mutations in DMD gene
Pt N. BMD vs
DMD
Mutation Effect of
mutation
Exon/
intron
Stop
codon
Reference Age of onset/
diagnosis(ys)
Symptoms at
onset
CK levels
(UI/L)
Age
CK
Loss of
ambulation (age)
I BMD Insertion c.10453insC p.Leu3485ProfsX6 74 [33] 7 HyperCKemia 12922 7 No (9)
II BMD Nonsense c.9G>A p.Trp3X 1 TGA [10] 3 HyperCKemia 3300 3 No (7)
III BMD Nonsense c.10783C>T p.Gln3595X 75 TAG [35] nd nd nd nd Yes (22)
IV BMD Missense c.352T>A p.Trp118Arg 5 Novel 45 Motor impairment nd nd No (49)
V BMD Splicing c.1705-8T>C cDNA analysis
NOT done
IVS14 Novel 2 hyperCKemia 1604 2 No (5)
VI BMD Splicing c.6118-3C>A cDNA analysis NOT
done
IVS42 Novel 49 Motor impairment 1400 46 No (68)
VII DMD Insertion c.151insC p.Leu51ProfsX37 3 Novel nd nd nd nd nd
VIII DMD Duplication c.3009dupTG p.Lys1004X 23 Novel nd nd nd nd nd
IX DMD Duplication c.5773_5794dup p.Gln1932ArgfsX6 41 Novel 1 HyperCKemia 2956 17 Yes (12)
X.1 DMD Insertion c.7548insGGCAACA p.
Met2517GlyfsX49
52 Novel nd nd nd nd nd
X.2 DMD Insertion c.7548insGGCAACA p.
Met2517GlyfsX49
52 Novel nd nd nd nd nd
XI DMD Deletion c.6353delA p.Gln2118ArgfsX3 44 Novel 2 HyperCKemia 16159 2 No (13)
XII.1 DMD Deletion c.6986delA p.Lys2329SerfsX8 48 [37] 1 HyperCKemia 11493 1 No (1)
XII.2 DMD Deletion c.6986delA p.Lys2329SerfsX8 48 [37] 3 Motor impairment 32359 3 No (4)
XIII DMD Deletion c.9204_9207delCAAA p.Asn3068LysfsX19 62 Leiden
database
4 HyperCKemia 7671 6 Yes (8)
XIV DMD Deletion c.10386delT p.Asn3462LysfsX3 73 Novel nd nd 4760 11 Yes (12)
XV.1 DMD Del/ins c.1603delGTAinsCT p.Val535LeufsX47 14 Novel nd nd 12000 9 Yes (13)
XV.2 DMD Del/ins c.1603delGTAinsCT p.Val535LeufsX47 14 Novel nd nd 2061 13 Yes (12)
XV.3 DMD Del/ins c.1603delGTAinsCT p.Val535LeufsX47 14 Novel nd nd 5357 9 Yes (10)
XVI DMD Nonsense c.568C>T p.Gln190X 7 TAG [10] 3 Motor impairment 12800 6 No (6)
XVII DMD Nonsense c.2956C>T p.Gln986X 23 TAA [35] 3 Motor impairment 10430 3 Yes (11)
XVIII DMD Nonsense c.3580C>T p.Gln1194X 26 TAG [10] 3 HyperCKemia 13580 3 No (7)
XIX DMD Nonsense c.4117C>T p.Gln1373X 30 TAG Leiden
database
2 HyperCKemia 7246 5 No (6)
XX DMD Nonsense c.4996C>T p.Arg1666X 35 TGA 38] 1 Delayed motor
milestones
8000 1 No (7)
XXI DMD Nonsense c.5209C>T p.Arg1737X 37 TAA Novel 2 HyperCKemia nd nd No (2)
XXII DMD Nonsense c.5530C>T p.Arg1844X 39 TGA [38] 3 Motor impairment 19000 5 No (6)
XXIII.1 DMD Nonsense c.5563C>T p.Gln1855X 39 TAG [35] 3 HyperCKemia 19452 4 No (7)
XXIII.2 DMD Nonsense c.5563C>T p.Gln1855X 39 TAG [35] 2 No symptoms nd No (5)
XXIV DMD Nonsense c.6277A>T p.Lys2093X 43 TAG Novel 1 Delayed motor
milestones
17000 1 No (5)
XXV.1 DMD Nonsense c.6943G>T p.Glu2315X 48 TAA [39] 3 Motor impairment 1918 12 Yes (8)
XXV.2 DMD Nonsense c.6943G>T p.Glu2315X 48 TAA [39] 3 Motor impairment 7583 9 No (8)
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2Table 1 Clinical and molecular characteristics of patients carrying point mutations in DMD gene (Continued)
XXVI DMD Nonsense c.8038C>T p.Arg2680X 55 TGA [40] 4 Delayed speech 3211 11 Yes (9)
XXVII DMD Nonsense c.8608C>T p.Arg2870X 58 TGA Leiden
database
1 Delayed motor
milestones
12954 9 No (10)
XXVIII DMD Nonsense c.8944C>T p.Arg2982X 60 TGA [38] 4 Delayed motor
milestones
8617 7 No (8)
XXIX DMD Nonsense c.9100C>T p.Arg3034X 61 TGA [10] 6 Delayed motor
milestones
15000 1 No (8)
XXX DMD Nonsense c.10108C>T p.Arg3370X 70 TGA [40] 4 Delayed motor
milestones
8891 1 No (9)
XXXI DMD Nonsense c.10108 C>T p.Arg3370X 70 TGA [40] 4 Delayed motor
milestones
2312 10 Yes (10)
XXXII DMD Nonsense c.10141C>T p.Arg3381X 70 TGA [40] nd nd nd nd No (4)
XXXIII DMD Nonsense c.10219G>T p.Glu3407X 70 TAA Novel 4 HyperCKemia 9200 4 No (11)
XXXIV DMD Nonsense c.10651C>T p.Gln3551X 75 TAG Novel 1 Delayed motor
milestones
13672 2 nd
XXXV DMD Splicing c.9560A>G p.Asp3187Gly 65 [39] 4 HyperCKemia 17634 5 No (6)
XXXVI DMD Splicing c.358-2A>T cDNA analysis
NOT done
IVS5 [10] 4 nd 3904 10 Yes (8)
XXXVII DMD Splicing c.2949+1G>T cDNA analysis
NOT done
IVS22 [12] nd Delayed motor
milestones
11834 1 nd
XXXVIII DMD Splicing c.6118-1G>A cDNA analysis
NOT done
IVS42 Leiden
database
nd nd nd nd
XXXIX DMD Splicing c.8668+3A>T cDNA analysis
NOT done
IVS58 Novel 3 HyperCKemia 11815 3 Yes (10)
XL DMD Splicing c.9563_9564ins53 p.Thr3188=fsX7 IVS65 Novel 4 HyperCKemia 16000 4 No (6)
XLI DMD Splicing c.10086+1G>A cDNA analysis
NOT done
IVS69 [36] 1 Delayed motor
milestones
7365 1 Yes (9)
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2weight, corresponding to the exon 43-deleted product
(Figure 4B, lower transcript). The data were therefore
consistent with the hypothesis that a leaky out-of-frame
splice defect led to the production of a decreased
amount of normal full-length DYS cDNA and a
decreased amount of normal dystrophin.
Patient XXXV: Coding region point mutation activates a
cryptic exonic splice site
A 4-year-old boy presented with occasionally high CK
levels (17,634 IU/L) confirmed at further analysis. At
6 years of age, he displayed moderate proximal muscle
weakness in the upper and lower limbs with positive
Gowers’ manoeuvre, and was started on corticosteroid
therapy. Patient XXXV also showed mild cognitive
impairment with difficulties at elementary school. He
had no cardiac or respiratory involvement.
Muscle biopsy obtained from brachial biceps demon-
strated a dystrophic pattern. IHC analysis showed a com-
plete absence of dystrophin. Multiplex-PCR and MLPA
analysis revealed no deletions or duplications. Gene
sequencing revealed a novel substitution (c.9560A>G) in
o n eo ft h el a s tn u c l e o t i d e so fe x o n6 5( F i g u r e5 A ) .
Although the mutation predictably causes a missense
mutation that results in an amino acid change at position
3187 (p.Asp3187Gly), this hypothesis did not fit with the
clinical presentation of the patient.
Through transcript analysis we ascertained that this
nucleotide substitution determines the activation of a
cryptic splice site, resulting in skipping of the last four
Exon 74
p.Leu3485ProfsX6
Pt Pt Ctr Ctr
DYS1 DYS2
AB
Ctr
AG GAC TCC CCC CTG AGC CAG CCT CGT AGT …
QDSP L SQ PRS
c.10453insC Pt
AG GAC TCC CCC CCT GAG CCA GCC TCG TAG
QDSP PEP ASX
Figure 2 Patient I: stop codon at the 3’ end of DMD gene in mild BMD phenotype. Molecular and muscle biopsy features in patient I. The
patient showed a mild BMD phenotype and carried a mutation that creates a stop codon at the 3’ end of the DMD gene. In the upper part of
the figure, the schematic representation of the DMD gene depicts the position of the mutation, which is located in exon 74. A. Sequence
analysis of genomic DNA. Pt (Patient I): The electropherogram depicts the single base pair insertion c.10453insC (black arrow). Under the
electropherogram, the predicted amino acid sequence demonstrates the effect of the mutation, which leads to the out-of-frame transcript p.
Leu3485ProfsX6. Ctr: Control. B. Dystrophin Western blot analysis of a muscle biopsy sample from patient I revealed decreased immunoblot
staining with antibody directed against the dystrophin mid-rod domain (DYS1), and absence of signal with antibodies directed towards the
C-terminal epitope (DYS2). Ctr: Control muscle sample.
Figure 3 Patient III: Nonsense mutation at the 3’ end of DMD
gene in severe BMD phenotype. The mutation is localized in
exon 75 (see schematic representation of the DMD gene). Sequence
analysis revealed the nucleotide substitution c.10783C>T (black
arrow). This mutation leads to the creation of a stop codon (p.
Gln3595X).
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Page 7 of 12nucleotides of exon 65 with consequent change of the
reading frame and creation of an out-of-frame transcript
(Figure 5B). Nucleotide substitutions located near
intron-exon boundaries mimicking missense mutations
can modify the splicing process, creating a new splice
site even if they are not located in typical splice sites.
Patient XL: An intronic nucleotide substitution activates a
cryptic splice site and leads to pseudoexon creation
This patient came to our attention as a 4-year-old boy
presenting with occasionally high CK levels (7,000 IU/L).
He was the first boy of healthy parents with a family his-
tory negative for muscle disorders. At first evaluation, he
showed mild calf hypertrophy and frequent falling. Dur-
ing the following two years he developed mild proximal
lower limb weakness with Gowers’ sign and running diffi-
culties. Patient XL never learned to run and was able to
climb the stairs only with the aid of a handrail. He had
no cardiac, respiratory, or cognitive impairments.
At 6 years of age, Patient XL underwent muscle
biopsy on the brachial biceps. Muscle tissue analysis
revealed a dystrophic pattern with moderate fibre size
variability, rare nuclear centralization, and fibre split-
tings, as well as few instances of necrosis. Interstitial cel-
lular infiltrates were absent. Connective tissue was
increased. IHC analysis demonstrated the complete
a b s e n c eo fd y s t r o p h i no nm u s c l em e m b r a n ew i t ht h e
antibodies directed against all three epitopes. A mild
reduction with a-SG antibodies was also present.
The DMD gene was investigated, with multiple-PCR
and MLPA excluding the presence of deletions and
duplications. Sequence analysis did not demonstrate the
presence of point mutations. cDNA analysis showed the
existence of a band of higher molecular weight than
expected (Figure 6A). Direct sequencing of RT-PCR pro-
ducts revealed the insertion of 53 bp (c.9563_9564ins53)
between exons 65 and 66 (Figure 6B). Further analysis
demonstrated that the inserted fragment corresponded to
a portion of intron 65. Its insertion into natural transcript
determines the creation of a premature stop codon
(p.Thr3188 = fsX7), which is responsible for the complete
absence of dystrophin at IHC analysis.
To better understand the molecular mechanism
underlying this genetic rearrangement, we further
g.DNA
exon 43 intron 42
c.6118-3C>A
cDNA
exon 42 exon 44
exon 42 exon 43
IVS 42
665 bp
493 bp
Pt Ctr
AC B
Figure 4 Patient VI: Leaky splice site mutation and double transcript in a BMD patient. The mutation is localized within intron 42 (see
schematic representation of the DMD gene reproduced in the upper part of the figure). A. Genomic analysis of the 3’ splice site of intron 42 in
patient VI. The electropherogram depicts the nucleotide substitution c.6118-3C>A in IVS42 (red box). B. Agarose gel electrophoretic analysis of
PCR products derived from the RT-PCR of DMD cDNA nucleotides 5959-6624 form patient VI’s muscle-derived cDNA. Transcript analysis reveals
the presence of two different RT-PCR products in the patient (Pt): the expected 665-bp full-length band, and a shorter 493-bp band; the RT-PCR
product from a control subject demonstrates the presence of the wild-type 665-bp band. C. Sequence analysis of the RT-PCR products
demonstrates that the 665-bp band corresponds to the full-length cDNA, while the 493-bp band corresponds to a product carrying the deletion
of exon 43.
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substitution at position -426 in intron 65 (c.9564-426
T>G); this mutation is located 5 bp downstream from
the inserted sequence. It has not been previously
described, and had a “de novo” origin since it was not
present in the patient’s mother.
Bio-informatic analysis (Figure 6C) showed that this
mutation is localized in a silent splice site consensus
sequence included in the intron. The substitution involves
one of the most important and conserved bases of the
sequence and markedly increases the splice site strength,
changing the maxENT score from a value of 6.8 in wild
type to a value of 10.4 in the patient, and making it higher
than is found in normal exons (8.1). The activation of this
criptic 5’splice site and its interaction with one pre-exist-
ing, but normally silent, acceptor splice site within intron
65 leads to the insertion of a 53-bp pseudoexon.
Discussion
We performed a clinical and molecular study of a sam-
ple of 47 Italian dystrophinopathic patients (41 DMD
and 6 BMD) carrying nucleotide alterations in the DMD
gene. All types of mutations were represented, including
10 micro-insertions or deletions, 21 nonsense substitu-
tions, 9 splice-site mutations, and 1 missense mutation.
Overall 16 of these mutations had not been previously
described.
From this cohort, we presented in detail five cases
paradigmatic of mechanisms that are responsible for
complex rearrangements or novel exceptions to the
reading frame rule. Two patients carried nonsense
mutations associated to unexpected BMD phenotype,
the other three represent unconventional splice-site
mutations, not localized in canonical splice sites or with
variable transcriptional effects. Three of these five inter-
esting mutations are also novel.
Nonsense mutations potentially determine the inter-
ruption of dystrophin synthesis, mRNA decay, and
degradation of truncated dystrophin molecules, unless
they are located in the 5’ or 3’ gene regions [31,32]. In
particular, two mechanisms are thought to be responsi-
ble for the variable effect of nonsense mutations located
in these gene regions, namely initiation of translation
from downstream ATG codons (in the case of muta-
tions located at the 5’ end) and escape from nonsense-
mediated decay (for substitutions in the 3’ portion). In
our sample, patients I and III carried a nonsense muta-
tion located at the 3’ of the gene associated with a BMD
phenotype of variable severity, with partial production
of dystrophin protein demonstrated by IHC and WB
analysis (Figure 2). Similar results have been described
in other cases. A detailed analysis of the Leiden database
http://www.dmd.nl indicates that the majority of
mutations located in the final 5 exons of the dystrophin
gene, even if determining production of an out-of frame
transcript, are associated with BMD or intermediate
phenotypes; only 11 are associated with DMD. In parti-
cular, the c.10453insC mutation has been described in 5
different patients: 1 showed a DMD phenotype; 2 had a
mild Becker-like muscular involvement; and 2 subjects,
of African and French origin, presented with an inter-
mediate phenotype [33-34, Leiden muscular dystrophy
database].
The mutation c.10783C>T has been described once
[35] in one DMD patient. We hypothesize that the
mutations located at the end of DMD cDNA bypass
mRNA decay as previously demonstrated [32], preser-
ving the protein functional domains responsible for
anchorage of the protein to the membrane.
While the efficiency of nonsense-mediated mRNA
decay can differ among patients carrying different distal
mutations, leading to different phenotypes, the mechan-
isms influencing this process are not known. Further-
more, this high spectrum of variability, which is also
evidenced among BMD presentations, suggests the influ-
ence of other factors that remain to be investigated. The
exact location of the mutation may also be considered
an important factor. It is worth mentioning that in
some cases nonsense mutations at the 3’ end of the
gene can be associated with the DMD phenotype, as
well, as we observed in two patients carrying two
g.DNA
mRNA
c.9560A>G (p.Asp3187Gly)
intron 65 exon 65
Pt
Ctr
exon 66 exon 65 del ATAC
exon 66 exon 65
Exon 65
A
B
Figure 5 Patient XXXV: Coding region point mutation activates
a cryptic exonic splice site. The mutation is localized in exon 65
(see schematic representation of the DMD gene). A. Sequence
analysis. An electropherogram depicting the nucleotide substitution
c.9560A>G, which would putatively result in an amino acid
substitution (p.Asp3187Gly). B. Transcript analysis. The nucleotide
substitution activates a cryptic splice site with skipping of the last 4
nucleotides of exon 65 (Pt: patient; Ctr: control), which changes the
reading frame.
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p.Asn3462LysfsX3).
Interesting insights into dystrophin mRNA maturation
may be derived from patients VI, XXXV, and XL, who
carry different mutations affecting the splicing process.
The mechanisms that determine alternative splicing
are complex and still not completely characterized. To
date, disease-causing splicing mutations described in
D M Da n dB M Dp o p u l a t i o n ss e e m st om a i n l ya f f e c t
canonical splice site sequences; the effect of these muta-
tions on mRNA processing has been investigated in few
published cases [17].
The behaviour of mutations involving the splice site is
not always completely predictable: in patient VI a leaky
novel splice site mutation determines the simultaneous
creation of two PCR products reflecting the presence of
both a full length and a spliced transcript (Figure 4).
The efficiency of the novel splicing signal inversely
correlates with disease severity and must be considered
when predicting the effect of the mutation. The case of
patient XXXV demonstrates how splicing can be altered
not only by mutations localized in the canonical splice
sites, but also by mutations in the neighbouring exonic
sequences. A nucleotide substitution located near the
exon-intron boundary, first interpreted as a missense
mutation, was demonstrated to have a strong effect on
splicing. This substitution determines the activation of a
cryptic splice site, resulting in skipping of the last four
nucleotides of exon 65, with a consequent reading frame
shift resulting in a severe phenotype (Figure 5).
Figure 6 Patient XL: An intronic nucleotide substitution activates a cryptic splice site leading to pseudoexon creation. The mutation is
localized in intron 65 (see schematic representation of the DMD gene). A. Sequence analysis. The electropherogram depicts the insertion of 53
bp between exons 65 and 66. This insertion creates a stop codon (TGA, red box) and results in the production of a truncated protein (p.
Thr3188ThrfsX7). The insertion is determined by a nucleotide substitution (c.9564-426T>G) in IVS 65, which activates a cryptic splice site. The
schematic representation of IVS65 under the electropherogram depicts the position of the intronic mutation and the sequence inserted into
intron 65. B. cDNA analysis depicts a band with higher molecular weight than control (Ctr) in the patient, demonstrating the insertion of 53 bp.
C. Bioinformatic analysis: 5’ Splice Site score distribution in patient (mutated, green) versus control (wild type, blue). The mutation is localized in a
silent splice site consensus sequence included in the intron and increases the MaxENT score, that gives the probability that a sequence is a
functional splice site, from a value of 6.8 to a value of 10.4. The obtained maxENT scores, suggest that the mutation activates a cripitc 5’ss
leading to inclusion of the exon in the mature transcript. The substitution involves one of the most important and conserved bases of the
consensus sequence, as shown in the schematic representation on the right, which illustrates the relative frequency of different bases in the 5’
splice site consensus sequence (the size of the letter indicating each nucleotide reflects its importance in the consensus sequence).
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deep intronic regions located at sites that can be recog-
nized as splice site consensus sequences. In these cases,
transcript analysis associated with bioinformatic predic-
tions may allow the clarification of molecular mechan-
isms underlying the disease phenotype. So far, the
creation of additional splice sites in the central part of an
intron has been reported in few cases [13,36]. In patient
XL, a single nucleotide substitution in a consensus
sequence that is normally silent increases its efficiency
and determines the insertion of a pseudo-exon (Figure 6).
Conclusion
All these cases underscore the importance of a complete
study of the gene, including exon-intron boundary sequen-
cing and transcript analysis, which has been demonstrated
to be the only definitive analysis. Nonetheless, muscle
biopsy remains highly informative because dystrophin
mRNA is hardly extracted from blood samples and dystro-
phin protein can be analyzed in muscle tissue.
Also, when a complete molecular characterization is
achieved, the interpretation of genetic data “per se”
might be challenging. The reading frame rule can be
used to predict the effect of the majority of mutations,
but some exceptions have been described, especially
among nucleotide alterations. Occasionally, these excep-
tions may provide support for another general rule, as it
occurs with the stop codon point mutations located in
the 5’ part of the DMD gene whereby the initiation of
translation occurs from downstream AUG codons and
results in BMD phenotypes [30]. However such a gen-
eral rule can be hardly recognized for patients carrying
nonsense mutations located at 3’ part of the gene, that
may lead to DMD, intermediate or BMD phenotypes
without an apparent rationale. In other instances, such
as the splicing variants described in patient VI and
XXXV, the molecular data evaluation should incorporate
both mRNA data and bioinformatic predictions in order
to draw a reliable conclusion on expected phenotype.
These instances support the notion that only a thor-
ough investigation of clinical features, muscle biopsy
data and molecular findings would finally give to the
molecular data interpretation a prognostic value in all
dystrophinopatic patients.
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